中国平安（601318）：中国平安发行H股可转债，集团资本实力进一步充实

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][7] Core Views - The company announced on June 4 that it plans to issue HKD 11.765 billion in H-share convertible bonds to support its capital needs and strategic development in healthcare and elderly care [2][7] - The issuance of the convertible bonds is expected to enhance the company's capital strength at a lower cost, following a previous USD 3.5 billion convertible bond issuance completed in July 2024 [7] - The company's solvency ratios have improved significantly, with core and comprehensive solvency ratios at 163.7% and 227.9% respectively as of Q1 2025, reflecting a 47 percentage point and 39 percentage point increase from the beginning of the year [7] Financial Forecasts - Total revenue is projected to reach CNY 1,028,925 million in 2024, with a year-on-year growth of 12.6% [7] - The net profit attributable to shareholders is expected to rebound to CNY 126,607 million in 2024, representing a 47.8% increase year-on-year [7] - The estimated earnings per share (EPS) for 2025 is CNY 7.42, with a projected price-to-earnings (P/E) ratio of 7.25 [9] - The company's price-to-embedded value (PEV) is forecasted to be 0.65x in 2025, indicating it is still undervalued [7][9] Market Data - The closing price of the company's stock is CNY 53.85, with a market capitalization of CNY 980,621.13 million [5] - The company has a price-to-book (P/B) ratio of 1.04 and a net asset value per share of CNY 51.60 [5][6] Capital Structure - The convertible bonds will be zero-coupon bonds maturing in 2030, with an initial conversion price of HKD 55.02, representing an 18.45% premium over the closing price on June 3 [7] - The issuance will utilize 28.7% of the general authorization limit approved by the shareholders [7]